Concerns about a drug manufactured by GlaxoSmithKline linked with heart attacks are on a rise. This came following a Senate report, which is now, is putting pressure on the Food and Drug Administration to make changes to its drug-safety program.

People reported that calls were held over the weekend to discuss on how to go about addressing the complaints coming in from from Sens. Max Baucus (D., Mont.) and Chuck Grassley (R., Iowa), who released a new report called Avandia on Saturday on the Glaxo drug.

A meeting of the advisory committee would be called in to review the information regarding the drug. Glaxo reported that it had a global sales of £771 million ($1.2 billion) in 2009.

An investigation that was conducted by the Senate Finance Committee, reports that Glaxo was aware about data linking Avandia to elevated risk of cardiovascular events for quite sometime but it underplayed the facts and doctors who raised a voice were repressed.

Glaxo however stated that this was not true. It said," The company says it never tried to suppress doctors' views but sought to correct what it considered misinformation.”

FDA commissioner Margaret Hamburg said, "The FDA takes very seriously concerns and issues raised in the recent inquiry. The FDA awaits its advisers' recommendation and in the meantime.”

Dr Hamburg plans to see FDA scientists alongwith with some experts to gain a detailed background of the report.